Niagen Bioscience, Inc. — Director's Dealing 2021

Mar 17, 2021

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: ChromaDex Corp. (CDXC)
CIK: 0001386570
Period of Report: 2021-03-15

Reporting Person: Jaksch Frank L Jr (N/A)

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2021-03-15	Employee Stock Options (right to buy)	$11.83	A	25072	Acquired	2031-03-14	Common Stock (25072)	Direct

Footnotes

F1: Options vest 33% on March 15, 2022 and thereafter 1/36th vest each month.